3 completed, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Essential Thrombocytosis: new trials by email Literature Review of Essential Thrombocytosis trials Research Report on Essential Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
| Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis lestaurtinib - Polycythemia Vera, Essential Thrombocytosis | Phase 2 | Completed | Cephalon | 39 | 2007-12-01 | 2015-10-08 |
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders Polycythemia Vera, Essential Thrombocytosis | Completed | National Institutes of Health Clinical Center (CC) | 8 | 2007-02-06 | 2017-07-02 |
Thrombocythemia, Essential (4) · Myeloproliferative Disorders (3) · Polycythemia Vera (3) · Primary Myelofibrosis (3) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Precancerous Conditions (1) · Preleukemia (1)
Blood Coagulation Disorders (4) · Blood Platelet Disorders (4) · Hemic and Lymphatic Diseases (4) · Hemorrhagic Disorders (4) · Thrombocytosis (4) · Bone Marrow Diseases (3) · Bone Marrow Neoplasms (3) · Hematologic Diseases (3) · Hematologic Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Leukemia, Myeloid (2) · Chronic Disease (1) · Disease Attributes (1) · Leukemia (1)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · CPI-0610 (1) · lestaurtinib (1) · ruxolitinib (1) · talazoparib (1)
Cephalon (1) · Constellation Pharmaceuticals (1) · Fox Chase Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1)
United States (4) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Peter Abdelmessieh, DO, MSc (1)
PMID 24903629, PMID 36881782, PMID 37530627, PMID 38259250
2018 (1)